Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus.
about
Lipids in liver transplant recipientsCardiovascular risk factors following renal transplantPathogenesis of calcineurin inhibitor-induced hypertensionCardiovascular diseases after kidney transplantation in Korea.New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.Strategies for minimizing immunosuppression in kidney transplantation.Cardiovascular complications of immunosuppressive agents in renal transplant recipients.Assessment of Arterial Stiffness, Volume, and Nutritional Status in Stable Renal Transplant Recipients.The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.Medical Management of Metabolic Complications of Liver Transplant Recipients.Dyslipidemia after kidney transplantation and correlation with cyclosporine level: a glimpse into the future.Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents.Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.Cardiovascular morbidity and mortality after kidney transplantation.The safety of calcineurin inhibitors for kidney-transplant patients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Individualized immunosuppression in transplant patients: potential role of pharmacogenetics.Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients.
P2860
Q26750468-073166A3-6DD3-48F8-9EF8-68907ADDD330Q26771406-9C9317A8-285C-49A4-BE36-44D120553337Q33723923-40BA57BF-A8C5-4FE0-A26A-A0196C095190Q34255588-323F69B1-27D3-40A7-91F5-A64058CD1ACFQ35153309-3E89D97E-5BA7-4505-943D-4FA84E43803BQ35990853-C1AF8821-F4EF-4AA5-85E2-66FB882ECA01Q36040739-79140E64-8B0D-439E-848A-81115D51AD7FQ36581199-D3BDF70A-DF5F-4612-A9D5-AFD842F70925Q36742552-B0B98795-6BB1-4ED0-ABCC-AB722C376E67Q37421526-F983B183-49FC-4E25-8BF5-F0FF8D915A6BQ37639119-5F660C57-AD93-43CB-B0FE-D2973298F340Q37859368-361C3E07-6416-4388-8E35-CAC246FC3108Q38063962-7CEFB9F9-A8D7-4756-AB31-A88588496E90Q38230449-80D3F89B-4FE6-4C4D-9870-07292EB801C1Q38235860-AE0F53CA-E660-4AD8-B95F-EF60F68D9BB2Q38578386-B939518A-A7C6-4177-99AA-348A231E9A8FQ38668601-8E8F467C-AB92-48B2-ADEF-8BCB50EF93EDQ42065624-8565A8CA-CE3A-4C5E-8E6B-FA9EACDF9940Q46936585-ABEB99E4-1DB2-40A7-8466-4E49D029F1D0Q47890626-AAD2985C-E674-4D87-B0D4-94DA5A5F9589
P2860
Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@en
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@nl
type
label
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@en
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@nl
prefLabel
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@en
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@nl
P2093
P1476
Improved cardiovascular risk p ...... om cyclosporine to tacrolimus.
@en
P2093
Fred C G J Sweep
Gerry Ligtenberg
Johannes M M Boots
Joke I Roodnat
Luuk B Hilbrands
Maarten H L Christiaans
Marika A Artz
Pierre N M Demacker
Pieter F Vos
P304
P356
10.1097/01.ASN.0000071515.27754.67
P50
P577
2003-07-01T00:00:00Z